Promis Neurosciences Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Promis Neurosciences Inc. (PMN) on December 12, 2025. The Company is incorporated in Ontario, Canada, and its common shares trade on the NASDAQ Capital Market. The report addresses a specific regulatory event regarding the Company's listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock price rather than financial performance metrics.
Material Changes
The primary material event is the resolution of a listing deficiency. On December 12, 2025, the Company received written notification from the Nasdaq Listing Qualifications Staff confirming it has regained compliance with the $1.00 minimum bid price requirement (NASDAQ Listing Rule 5550(a)(2)). This follows a deficiency notice issued on January 8, 2025, and a subsequent 180-day grace period extension granted until December 29, 2025.
Outlook and Management Commentary
Management confirmed that the closing bid price of the Company's common shares was $1.00 or greater for 10 consecutive business days from November 28, 2025, to December 11, 2025. The Company had previously indicated it would cure the deficiency, potentially through a reverse stock split if necessary, though the filing indicates the price requirement was met organically during the compliance window. The matter is now closed.
Investor Verification Checklist
- Verify the current trading price of PMN shares to ensure continued compliance with the $1.00 minimum bid price.
- Confirm the Company's stockholder equity status, which was a condition for the grace period extension.
- Monitor future filings for any indication of a reverse stock split if the share price falls below $1.00 again.
- Review the Company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains no financial statements.